Patents by Inventor Yasser KHDER

Yasser KHDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMENS OF FACTOR XI/XIA ANTIBODIES
    Publication number: 20240294669
    Abstract: This disclosure relates to dosage regimens for anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies or antigen-binding fragments thereof, pharmaceutical formulations comprising the same, and pharmaceutical formulations for use in the treatment of thromboembolic disorders or related conditions. Also provided are pharmaceutical formulations of anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof. Also provided are methods of treating patients having thrombocytopenias with anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies, or antigen-binding fragments thereof.
    Type: Application
    Filed: May 17, 2024
    Publication date: September 5, 2024
    Inventors: Debra A. FREEDHOLM, Daniel M. BLOOMFIELD, Royston J. GLASSPOOL, Jonathan E. FREEMAN, Yasser KHDER
  • METHODS FOR THE DETECTION OF ANTI-DRUG ANTIBODIES AGAINST FACTOR XI AND/OR FACTOR XIA ANTIBODIES
    Publication number: 20240077497
    Abstract: This disclosure relates to methods for detection and measurement of anti-drug antibodies (ADAs) against Factor XI and/or Factor XIa therapeutic antibodies, e.g., in a subject being treated with said Factor XI and/or Factor XIa therapeutic antibodies.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 7, 2024
    Inventors: Debra A. FREEDHOLM, Daniel M. BLOOMFIELD, Royston J. GLASSPOOL, Jonathan E. FREEMAN, Yasser KHDER
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20240067750
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: January 20, 2023
    Publication date: February 29, 2024
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • METHODS OF TREATMENT WITH ANTI-FACTOR XI/XIA ANTIBODIES
    Publication number: 20230002507
    Abstract: The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI (“Factor XIa”).
    Type: Application
    Filed: February 11, 2022
    Publication date: January 5, 2023
    Inventors: Carola FRIEDMAN, Yasser KHDER, Martin LEFKOWITZ
  • REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF
    Publication number: 20200317816
    Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 8, 2020
    Inventors: Stefan Ewert, Yasser KHDER, Alexander KOCH
  • METHODS OF TREATMENT WITH ANTI-FACTOR XI/XIA ANTIBODIES
    Publication number: 20200231701
    Abstract: The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI (“Factor XIa”).
    Type: Application
    Filed: December 22, 2017
    Publication date: July 23, 2020
    Inventors: Carola FRIEDMAN, Yasser KHDER, Martin LEFKOWITZ
  • Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
    Patent number: 10647780
    Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: May 12, 2020
    Assignee: Novartis AG
    Inventors: Stefan Ewert, Yasser Khder, Alexander Koch
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20200115468
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: September 24, 2019
    Publication date: April 16, 2020
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • Factor XI antibodies and methods of use
    Patent number: 10465011
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: November 5, 2019
    Assignee: Novartis AG
    Inventors: Jorg Eder, Stefan Ewert, Ulrich Hassiepen, Yasser Khder, Lorenz Mayr, Samu Melkko, Nikolaus Schiering
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20180355056
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 13, 2018
    Applicant: NOVARTIS AG
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING
  • REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF
    Publication number: 20180022825
    Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.
    Type: Application
    Filed: May 24, 2017
    Publication date: January 25, 2018
    Inventors: Stefan EWERT, Yasser KHDER, Alexander KOCH
  • FACTOR XI ANTIBODIES AND METHODS OF USE
    Publication number: 20170022292
    Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 24, 2016
    Publication date: January 26, 2017
    Applicant: NOVARTIS AG
    Inventors: Jorg EDER, Stefan EWERT, Ulrich HASSIEPEN, Yasser KHDER, Lorenz MAYR, Samu MELKKO, Nikolaus SCHIERING